Consultation Form
Treetop Health Will Follow FDA's Directive on Ceasing Compounding Supply of Tirzepatide
Based on FDA's guidance published on 12/19/24, compounded tirzepatide supply must stop. A grace period of until 2/18/25 (503As) or 3/19/25 (503Bs) was granted to some compounded pharmacies. This page will be updated accordingly.
Fill out this form to get access to our program. We will get back to you within 24 hours.
